ReviewPediatric research2025
Perspective Review: Advancing toward the diagnosis of sarcopenia in the pediatric population.
Review in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Growth Trajectory to Functional Decline: Age-Contextualized Nutritional Strategies for Muscle Vulnerability. A Narrative Review.Nutrients · 2026Review
- Muscle mass, strength, and sarcopenia in juvenile idiopathic arthritis: a scoping review.Pediatric rheumatology online journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is a muscle disorder characterized by the progressive loss of muscle mass and strength, leading to diminished physical performance. Although primarily associated with aging and chronic diseases, it is increasingly recognized in younger populations, particularly among those with chronic illnesses. Recent evidence suggests that muscle mass and strength deficits can manifest as early as childhood and adolescence, affecting three out of ten adolescents. Pediatric sarcopenia, while challenging to define due to the lack of standardized diagnostic criteria, presents significant health risks, including increased susceptibility to metabolic syndrome and chronic non-communicable diseases. Recent studies have attempted to establish normative values for muscle health in pediatric populations, yet many rely only on assessment of either muscle mass or strength, thus limiting the understanding of overall muscle health. In this context, the interaction between muscle mass, strength, and functionality, herein referred to as the muscle mass-strength-functionality triad (MSFt), is crucial for understanding the onset and progression of pediatric sarcopenia. The present review provides a perspective on concepts and operators defining pediatric sarcopenia and advocates for incorporating novel diagnostic criteria encompassing the MSFt. Furthermore, the importance of physical literacy and the acquisition of fundamental movement skills during childhood is highlighted, as these factors significantly influence long-term muscle health and physical activity levels. IMPACT: This perspective review provides an insightful view of muscle health in children and adolescents centered around the definition of pediatric sarcopenia. We discussed how to understand and describe sarcopenic-like deficits in pediatric populations. We propose the muscle mass-strength-functionality triad as an attribute that describes physical competence and is key to defining pediatric sarcopenia. We suggest the addition of physical literacy and movement competence assessment to the current diagnostic criteria of pediatric sarcopenia.
Identifiers
41454144What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.